What is Survodutide?
Survodutide is a dual agonist of the GLP-1 and glucagon receptors under investigation for obesity and metabolic-associated fatty liver disease (MASH). It combines appetite regulation with effects on energy expenditure.
Also known as: BI 456906
How Survodutide is studied
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors. Combining appetite regulation with glucagon-driven energy expenditure, it is under study for obesity and for metabolic-associated fatty liver disease (MASH).
Commonly researched for
Research status
Important considerations
Not approved. Investigational compound; use only under medical supervision.
Survodutide — frequently asked questions
Weight management, liver health (MASH), and broader metabolic outcomes. It is investigational.
It activates both GLP-1 and glucagon receptors, whereas semaglutide targets GLP-1 alone. It is still in clinical development.
No. It is investigational and not approved for use.